RELATIONSHIP OF CD27, CD28, CD81, AND CD117 MARKERS WITH TREATMENT RESPONSE AND PROGNOSIS IN MULTIPLE MYELOMA
Bozok Tıp Dergisi · 15.06.2026 · 16 (2) · 202-214
DOI: 10.16919/bozoktip.1805472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bozok Tıp Dergisi, online erschienen am 15.06.2026. Verfasst von Mine Büşra Bozkürk und 9 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to evaluate the relationship between CD27, CD28, CD81, and CD117 antigens and clinical, biochemical, and cytogenetic parameters in patients with multiple myeloma (MM) and to evaluate their prognostic significance.Material and Methods: A retrospective analysis was performed on data from 100 multiple myeloma patients. The analysis included available flow cytometry data (CD27, CD28, CD81, and CD117) and bone marrow biopsy results. Demographic data, laboratory parameters, cytogenetic analyses, treatment responses, and mortality were recorded. Multivariate logistic regression analysis was performed for variables associated with the R-ISS stages.
Results
The median age of the patients was 67 years, and 64% were men. The positivity rates for CD27, CD28, CD81, and CD117 were 45%, 53%, 61%, and 51%, respectively. As the R-ISS stage increased, CD27 negativity significantly increased (p=0.021), while CD117 positivity also increased (p=0.046). In the multivariate analysis, CD28 positivity emerged as an independent risk factor for a higher R-ISS stage (aOR=0.324 for CD28 negativity, p=0.015). CKS1B positivity (p=0.039) and a high bone marrow plasma cell ratio (p=0.004) were independently associated with advanced disease stages. As the R-ISS stage increased, ECOG performance scores worsened, and the number of lytic lesions and mortality rates significantly increased.
Conclusion
In multiple myeloma, CD27 loss and CD117 positivity are associated with poor prognosis, whereas CD28 positivity is associated with more advanced disease stage. The addition of these immunophenotypic markers to the R-ISS classification may contribute to a more accurate assessment of biological risk and the development of personalized treatment plans.
Zitieren
APA
Bozkürk, M. B., Topcuoglu, C., Güneş, A. K., Öztürk, A., Öztürk, H. B. A., Kalan, U., Yıldız, S., Acar, K., Özdemir, Ş., & Güçel, F. (2026). RELATIONSHIP OF CD27, CD28, CD81, AND CD117 MARKERS WITH TREATMENT RESPONSE AND PROGNOSIS IN MULTIPLE MYELOMA. Bozok Tıp Dergisi, 16(2), 202-214. https://doi.org/10.16919/bozoktip.1805472
Vancouver
Bozkürk MB, Topcuoglu C, Güneş AK, Öztürk A, Öztürk HBA, Kalan U, et al. RELATIONSHIP OF CD27, CD28, CD81, AND CD117 MARKERS WITH TREATMENT RESPONSE AND PROGNOSIS IN MULTIPLE MYELOMA. Bozok Tıp Dergisi. 2026;16(2):202-214. doi:10.16919/bozoktip.1805472
BibTeX
@article{Bozkrk2026,
author = {Bozkürk, Mine Büşra and Topcuoglu, Canan and Güneş, Ahmet Kürşad and Öztürk, Alpaslan and Öztürk, Hacer Berna Afacan and Kalan, Uğur and Yıldız, Selin and Acar, Kadir and Özdemir, Şeyda and Güçel, Funda},
title = {RELATIONSHIP OF CD27, CD28, CD81, AND CD117 MARKERS WITH TREATMENT RESPONSE AND PROGNOSIS IN MULTIPLE MYELOMA},
journal = {Bozok Tıp Dergisi},
year = {2026},
volume = {16},
number = {2},
pages = {202--214},
doi = {10.16919/bozoktip.1805472}
}
EUVIMED